EpicGenetics’ FM/a Blood Test for Fibromyalgia Is Now Available in Canada
EpicGenetics' FM/a Test for detecting fibromyalgia is now available in Canada.
FM/a was the first blood test for fibromyalgia to receive U.S. Federal Drug Administration approval— in 2012.
The test identifies white blood cell anomalies that are known to occur in those with the disease. It has a high accuracy rate, displaying 93% sensitivity in diagnosing fibromyalgia. This means the test identifies a person with the disease 93 percent of the time.
Patients whom the blood test diagnoses as having fibromyalgia will be able to take part in a genomic survey investigating genetic biomarkers for fibromyalgia, according to EpicGenetics. The hope is that the information will help scientists identify fibromyalgia-related mutations and genetic markers, similar to the BRCA1/BRCA2 genes that can predict breast cancer.
The company expects to include up to 250,000 patients in the survey. It will cover the costs.
“There has been tremendous response and interest from Canadians in receiving an accurate fibromyalgia diagnosis with the FM/a Test and in participating in our landmark clinical study efforts announced last month,” Dr. Bruce Gillis, EpicGenetics’ CEO, said in a news release. “We are excited to announce that we can now accommodate these patients and finally provide them with certainty about a commonly misunderstood and misdiagnosed disorder.”
" Joana Fernandes, PhD : Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology.."